


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:52Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12404864" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12404864</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>orthopsurg</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" id="os70113" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Orthop Surg</journal-id><journal-id journal-id-type="iso-abbrev">Orthop Surg</journal-id><journal-id journal-id-type="pmc-domain-id">3643</journal-id><journal-id journal-id-type="pmc-domain">orthopsurg</journal-id><journal-id journal-id-type="publisher-id">OS</journal-id><journal-title-group><journal-title>Orthopaedic Surgery</journal-title></journal-title-group><issn pub-type="ppub">1757-7853</issn><issn pub-type="epub">1757-7861</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12404864</article-id><article-id pub-id-type="pmcid-ver">PMC12404864.1</article-id><article-id pub-id-type="pmcaid">12404864</article-id><article-id pub-id-type="pmcaiid">12404864</article-id><article-id pub-id-type="pmid">40751278</article-id><article-id pub-id-type="doi">10.1111/os.70113</article-id><article-id pub-id-type="publisher-id">OS70113</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Clinical Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Article</subject></subj-group></article-categories><title-group><article-title>The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty&#8212;A Retrospective Cohort Study</article-title></title-group><contrib-group><contrib id="os70113-cr-0001" contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="Q">Qiyu</given-names></name><xref rid="os70113-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="os70113-cr-0002" contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="Z">Zhixin</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70113-cr-0003" contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="H">Hong</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70113-cr-0004" contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="W">Wai</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70113-cr-0005" contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xuming</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70113-cr-0006" contrib-type="author"><name name-style="western"><surname>Wan</surname><given-names initials="X">Xufeng</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70113-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="D">Duan</given-names></name><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>wangduan_bone@163.com</email></address></contrib><contrib id="os70113-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Zongke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9037-4756</contrib-id><xref rid="os70113-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>zongke@126.com</email></address></contrib></contrib-group><aff id="os70113-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">West China School of Medicine</named-content>
<institution>Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">People's Republic of China</country>
</aff><aff id="os70113-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopedic Surgery and Orthopedic Research Institution, West China Hospital</named-content>
<institution>Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Duan Wang (<email>wangduan_bone@163.com</email>)<break/>
Zongke Zhou (<email>zongke@126.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue seq="70">9</issue><issue-id pub-id-type="pmc-issue-id">496083</issue-id><issue-id pub-id-type="doi">10.1111/os.v17.9</issue-id><fpage>2570</fpage><lpage>2578</lpage><history><date date-type="rev-recd"><day>16</day><month>6</month><year>2025</year></date><date date-type="received"><day>01</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Orthopaedic Surgery</italic> published by Tianjin Hospital and John Wiley &amp; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="OS-17-2570.pdf"/><self-uri content-type="pdf" xlink:href="file:OS-17-2570.pdf"/><abstract><title>ABSTRACT</title><sec id="os70113-sec-0001"><title>Objective</title><p>Aseptic hip revision arthroplasty often results in significant postoperative pain, inflammation, nausea, and vomiting. While perioperative dexamethasone has demonstrated benefits in primary hip arthroplasty, its efficacy and safety in revision procedures remain unclear. This study aims to evaluate the effects of perioperative dexamethasone on postoperative pain, inflammation, postoperative nausea and vomiting (PONV), and safety in aseptic hip revision.</p></sec><sec id="os70113-sec-0002"><title>Methods</title><p>A retrospective cohort study was conducted on 414 patients undergoing aseptic hip revision arthroplasty between 2008 and 2023. Patients were categorized into two groups: those receiving dexamethasone perioperatively (<italic toggle="no">n</italic>&#8201;=&#8201;218) and a control group (<italic toggle="no">n</italic>&#8201;=&#8201;196). Outcomes included Visual Analog Scale (VAS) pain scores, inflammation markers including C&#8208;reactive protein (CRP) and interleukin&#8208;6 (IL&#8208;6), PONV incidence, analgesic and antiemetic usage, length of stay (LOS), and postoperative complications. Independent samples <italic toggle="no">t</italic>&#8208;test or Mann&#8211;Whitney <italic toggle="no">U</italic> test is applied to continuous variables based on normality, while chi&#8208;square test or Fisher's exact test is used for categorical variables according to sample size.</p></sec><sec id="os70113-sec-0003"><title>Results</title><p>The dexamethasone group (average dose: 12.67&#8201;mg) exhibited significantly lower VAS scores (<italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) and reduced morphine use on postoperative days (PODs) 1&#8211;3. CRP (POD2: 40.60&#8201;mg/L vs. 111.66&#8201;mg/L) and IL&#8208;6 levels (POD1: 31.85&#8201;pg/mL vs. 138.28&#8201;pg/mL) were significantly lower in the dexamethasone group (both <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001). PONV incidence (28.4% vs. 40.81%) and antiemetic usage were reduced in the dexamethasone group. No significant differences were observed in LOS or postoperative complications between the two groups.</p></sec><sec id="os70113-sec-0004"><title>Conclusion</title><p>Perioperative low&#8208;dose dexamethasone effectively mitigates pain, inflammation, and PONV in aseptic hip revision arthroplasty without increasing the risk of complications.</p></sec></abstract><abstract abstract-type="graphical"><p>We showed for the first time that perioperative administration of dexamethasone in patients undergoing aseptic revision hip arthroplasty can relieve postoperative pain, prevent PONV, and provide inflammation control without increasing the risk of surgical&#8208;site wound infections or dislocation.<boxed-text position="anchor" content-type="graphic" id="os70113-blkfxd-0001" orientation="portrait"><graphic position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="OS-17-2570-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="os70113-kwd-0001">aseptic hip revision arthroplasty</kwd><kwd id="os70113-kwd-0002">dexamethasone</kwd><kwd id="os70113-kwd-0003">inflammation</kwd><kwd id="os70113-kwd-0004">postoperative nausea and vomiting</kwd><kwd id="os70113-kwd-0005">postoperative pain</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2022YFC2503100</award-id><award-id>2022YFC2503104</award-id><award-id>2022YFC2503103</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82402773</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>West China Hospital of Sichuan University 1&#183;3&#183;5 Discipline Excellence Development Project</institution></institution-wrap></funding-source><award-id>ZYAI24023</award-id><award-id>ZYGD23033</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="9"/><word-count count="5900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:02.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="os70113-cit-1001"><string-name name-style="western"><given-names>Q.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Liao</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, et al., &#8220;<article-title>The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty&#8212;A Retrospective Cohort Study</article-title>,&#8221; <source>Orthopaedic Surgery</source><volume>17</volume>, no. <issue>9</issue> (<year>2025</year>): <fpage>2570</fpage>&#8211;<lpage>2578</lpage>, <pub-id pub-id-type="doi">10.1111/os.70113</pub-id>.<pub-id pub-id-type="pmcid">PMC12404864</pub-id><pub-id pub-id-type="pmid">40751278</pub-id></mixed-citation>
</p><fn-group id="os70113-ntgp-0001"><fn fn-type="funding" id="os70113-note-0001"><p>
<bold>Funding:</bold> This work was supported by National Key Research and Development Program of China (No. 2022YFC2503100, 2022YFC2503104, and 2022YFC2503103), National Natural Science Foundation of China, 82402773, West China Hospital of Sichuan University 1&#183;3&#183;5 Discipline Excellence Development Project, ZYAI24023, ZYGD23033.</p></fn><fn fn-type="equal" id="os70113-note-0002"><p>Qiyu Xie, Zhixin Liao are co&#8208;first authors and have contributed equally to this work.</p></fn></fn-group></notes></front><body id="os70113-body-0001"><sec id="os70113-sec-0005"><label>1</label><title>Introduction</title><p>Total hip arthroplasty (THA) is a transformative surgical intervention for end&#8208;stage hip diseases, offering substantial pain relief and improved joint function [<xref rid="os70113-bib-0001" ref-type="bibr">1</xref>, <xref rid="os70113-bib-0002" ref-type="bibr">2</xref>]. The procedure has revolutionized the management of advanced hip pathology, enabling patients to regain mobility and a better quality of life. Despite these benefits, complications such as periprosthetic joint infection, implant dislocation, and limited prosthesis longevity often necessitate revision surgeries. With an aging population and an increase in primary THA procedures, the demand for revision hip arthroplasty is expected to rise significantly [<xref rid="os70113-bib-0003" ref-type="bibr">3</xref>, <xref rid="os70113-bib-0004" ref-type="bibr">4</xref>]. Compared to primary THA, revision hip arthroplasty presents greater technical challenges and is associated with increased surgical trauma, heightened inflammatory responses, more severe postoperative pain, higher rates of postoperative nausea and vomiting (PONV), and longer hospital stays [<xref rid="os70113-bib-0005" ref-type="bibr">5</xref>, <xref rid="os70113-bib-0006" ref-type="bibr">6</xref>]. These complexities underscore the urgent need for orthopedic surgeons to adopt effective strategies to mitigate postoperative pain, control inflammation, and optimize recovery outcomes in patients undergoing revision hip arthroplasty.</p><p>Dexamethasone, a potent and long&#8208;acting glucocorticoid with well&#8208;established anti&#8208;inflammatory and analgesic properties, has shown promise in addressing these perioperative challenges [<xref rid="os70113-bib-0007" ref-type="bibr">7</xref>, <xref rid="os70113-bib-0008" ref-type="bibr">8</xref>, <xref rid="os70113-bib-0009" ref-type="bibr">9</xref>]. Its efficacy has been extensively studied in the context of primary THA, where it has been shown to significantly reduce postoperative pain and opioid consumption. Multiple studies have provided robust evidence supporting dexamethasone's ability to control inflammation and minimize complications such as PONV. For instance, a retrospective review of 376 patients undergoing primary direct anterior approach THA found that perioperative dexamethasone administration was associated with reduced postoperative pain and decreased reliance on opioid analgesics [<xref rid="os70113-bib-0010" ref-type="bibr">10</xref>]. Furthermore, research exploring optimized dosing regimens, such as a three&#8208;dose dexamethasone protocol, has demonstrated additional benefits, including enhanced pain relief, reduced nausea, improved inflammatory control, and faster postoperative mobility [<xref rid="os70113-bib-0011" ref-type="bibr">11</xref>]. In a randomized controlled trial, low&#8208;dose perioperative dexamethasone was associated with a reduced length of stay (LOS), with patients receiving dexamethasone showing an average LOS of 4.07&#8201;days compared to 4.84&#8201;days in the control group [<xref rid="os70113-bib-0007" ref-type="bibr">7</xref>].</p><p>Despite these promising results in primary THA, there remains a notable gap in the literature regarding dexamethasone's application in aseptic revision hip arthroplasty. While its benefits in primary procedures are well&#8208;documented, limited evidence exists on its safety and efficacy in revision settings. Patients undergoing revision arthroplasty face distinct challenges, including greater surgical complexity and heightened inflammatory responses, which make it crucial to investigate whether the advantages observed in primary THA extend to revision procedures. Additionally, there is no consensus on specific aspects of dexamethasone's perioperative efficacy in this context, such as its impact on pain management, PONV prevention, and inflammatory control.</p><p>To address these gaps, this retrospective, open&#8208;label cohort study was designed to systematically evaluate the clinical effects and safety profile of intravenous dexamethasone in patients undergoing aseptic revision hip arthroplasty. The study aimed to determine whether dexamethasone administration could achieve the following: (1) alleviate postoperative pain and control inflammation, reduce the number of patients requiring analgesia rescue, and decrease the demand for analgesia medications such as morphine; (2) prevent PONV, reduce the number of patients requiring antiemetic rescue, and evaluate the total consumption of antiemetic medications such as metoclopramide and ondansetron; and (3) achieve points (1) and (2) without significantly increasing the risk of treatment&#8208;related adverse effects. By addressing these objectives, this study seeks to provide valuable insights into the perioperative management of aseptic revision hip arthroplasty and potentially establish a new standard of care for improving patient outcomes in this challenging surgical context.</p></sec><sec sec-type="methods" id="os70113-sec-0006"><label>2</label><title>Methods</title><sec id="os70113-sec-0007"><label>2.1</label><title>Patients and Design</title><p>The study protocol was approved by the institutional review board of our institute (2024&#8211;1489) and registered with the International Clinical Trial Registry (ChiCTR2400091108). This retrospective study utilized medical records from prior clinical consultations, which had been granted a waiver of informed consent. The inclusion criteria include patients who underwent revision hip arthroplasty at our institute from January 2008 to December 2023. The exclusion criteria include: (i) patients who did not undergo revision hip arthroplasty for aseptic failure; (ii) patients with incomplete data during retrospective data collection.</p><p>A total of 432 patients underwent aseptic revision hip arthroplasty during the study period, of whom 18 were excluded due to incomplete data. Ultimately, 414 patients were included in the analysis. The control group consisted of 196 patients who did not receive dexamethasone during or after surgery, while the dexamethasone group included 218 patients who received the medication (mean dose: 12.67&#8201;mg; range: 3.75&#8201;mg&#8208;60&#8201;mg) intraoperatively, postoperatively, or both. Specifically, 144 patients received dexamethasone during the induction of anesthesia, 26 patients on postoperative day (POD) 1, and 48 patients during anesthesia induction as well as on POD 1.</p></sec><sec id="os70113-sec-0008"><label>2.2</label><title>Postoperative Care Protocol</title><p>All patients followed a standardized postoperative care protocol managed by five senior surgeons. Surgeries were performed under general anesthesia in a laminar airflow operating room. Post&#8208;anesthesia care involved a transfer to the recovery unit for approximately 2&#8201;h before returning to the inpatient unit. Postoperative pain management and PONV prevention protocols were identical for all patients. Intramuscular morphine was administered when patients reported a visual analog scale (VAS) pain score &gt;&#8201;4 on a 0&#8211;10 scale. For PONV management, intramuscular metoclopramide or ondansetron was provided for patients with &#8805;&#8201;2 episodes of nausea or vomiting or severe nausea. Medication dosages were adjusted based on the severity of symptoms. No other analgesic or antiemetic agents were used during the study period.</p></sec><sec id="os70113-sec-0009"><label>2.3</label><title>Outcome Measurements</title><p>Demographic information, medical histories, and concurrent medications were documented preoperatively. Patients were instructed on the use of the VAS scale to assess dynamic pain levels, which were recorded preoperatively and on PODs 1, 2, 3, 15, and 90. Postoperative morphine usage was also tracked. Inflammatory markers, including C&#8208;reactive protein (CRP) and interleukin&#8208;6 (IL&#8208;6), were measured preoperatively and on PODs 1, 2, 3, and 15. PONV incidence and the use of rescue antiemetic medications (metoclopramide and ondansetron) were documented postoperatively. Complications such as periprosthetic joint infection, aseptic failure, and dislocation were monitored during the hospital stay and at the 1&#8208;month follow&#8208;up.</p></sec><sec id="os70113-sec-0010"><label>2.4</label><title>Statistical Analysis</title><p>Statistical analyses were conducted using SPSS version 21 (IBM, Armonk, NY). Quantitative data were presented as means &#177; standard deviations or median (interquartile range, IQR), while qualitative data were expressed as frequencies and percentages. Normality tests were applied for all continuous variables. For continuous variables that did not conform to normality, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests were used, while <italic toggle="yes">t</italic>&#8208;tests were applied to those that conformed to normality. Chi&#8208;square tests or Fisher's exact tests were applied for categorical data. Statistical significance was defined as <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec sec-type="results" id="os70113-sec-0011"><label>3</label><title>Results</title><sec id="os70113-sec-0012"><label>3.1</label><title>Patients Demographics</title><p>The baseline characteristics and preoperative data of the two groups were comparable (Table&#160;<xref rid="os70113-tbl-0001" ref-type="table">1</xref>). There were no significant differences in age, gender, Body Mass Index, preoperative biological markers, preoperative VAS scores, or the presence of chronic conditions such as hypertension and diabetes.</p><table-wrap position="float" id="os70113-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of the patients undergoing aseptic revision hip arthroplasty.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Demographics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group, (<italic toggle="yes">n</italic>&#8201;=&#8201;196)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dex group, (<italic toggle="yes">n</italic>&#8201;=&#8201;218)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Statistical value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (y)</td><td align="center" valign="top" rowspan="1" colspan="1">63.19&#8201;&#177;&#8201;11.06</td><td align="center" valign="top" rowspan="1" colspan="1">63.00&#8201;&#177;&#8201;12.51</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;0.163</td><td align="center" valign="top" rowspan="1" colspan="1">0.871</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (female, %)</td><td align="center" valign="top" rowspan="1" colspan="1">48.47</td><td align="center" valign="top" rowspan="1" colspan="1">37.61</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>2&#8201;=&#8201;5.041</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (m)</td><td align="center" valign="top" rowspan="1" colspan="1">1.60 (0.10)</td><td align="center" valign="top" rowspan="1" colspan="1">1.58 (0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;1.341</td><td align="center" valign="top" rowspan="1" colspan="1">0.180</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">62.30&#8201;&#177;&#8201;10.01</td><td align="center" valign="top" rowspan="1" colspan="1">60.11&#8201;&#177;&#8201;10.61</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;2.124</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">23.83 (4.00)</td><td align="center" valign="top" rowspan="1" colspan="1">23.19 (4.55)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;1.772</td><td align="center" valign="top" rowspan="1" colspan="1">0.078</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preop HB</td><td align="center" valign="top" rowspan="1" colspan="1">133.56&#8201;&#177;&#8201;16.60</td><td align="center" valign="top" rowspan="1" colspan="1">132.35&#8201;&#177;&#8201;15.62</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;0.756</td><td align="center" valign="top" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preop CRP</td><td align="center" valign="top" rowspan="1" colspan="1">3.28&#8201;&#177;&#8201;1.96</td><td align="center" valign="top" rowspan="1" colspan="1">3.69&#8201;&#177;&#8201;2.09</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;&#8722;1.938</td><td align="center" valign="top" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preop IL&#8208;6</td><td align="center" valign="top" rowspan="1" colspan="1">3.45&#8201;&#177;&#8201;1.90</td><td align="center" valign="top" rowspan="1" colspan="1">3.63&#8201;&#177;&#8201;2.20</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;&#8722;0.754</td><td align="center" valign="top" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preop VAS of dynamic pain</td><td align="center" valign="top" rowspan="1" colspan="1">3.35&#8201;&#177;&#8201;0.61</td><td align="center" valign="top" rowspan="1" colspan="1">3.30&#8201;&#177;&#8201;0.47</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;0.843</td><td align="center" valign="top" rowspan="1" colspan="1">0.337</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preop FBG</td><td align="center" valign="top" rowspan="1" colspan="1">5.35 (0.90)</td><td align="center" valign="top" rowspan="1" colspan="1">5.19 (0.75)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;0.343</td><td align="center" valign="top" rowspan="1" colspan="1">0.730</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (33.16)</td><td align="center" valign="top" rowspan="1" colspan="1">67 (30.73)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;0.283</td><td align="center" valign="top" rowspan="1" colspan="1">0.596</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (10.20)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (11.47)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;0.168</td><td align="center" valign="top" rowspan="1" colspan="1">0.680</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (7.14)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (5.50)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;0.434</td><td align="center" valign="top" rowspan="1" colspan="1">0.493</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (5.10)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.38)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inflammatory disease <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (9.69)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (14.68)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;2.389</td><td align="center" valign="top" rowspan="1" colspan="1">0.123</td></tr></tbody></table><table-wrap-foot id="os70113-ntgp-0002"><fn id="os70113-note-0003"><p>
<italic toggle="yes">Note</italic>: For non&#8208;normally distributed data, we describe them using the median (interquartile range, IQR). Regarding statistical value, for the independent samples <italic toggle="yes">t</italic>&#8208;test, the results are presented as <italic toggle="yes">t</italic>&#8208;values; for the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, the results are shown as <italic toggle="yes">Z</italic>&#8208;values; for the chi&#8208;square test, the results are represented by <italic toggle="yes">X</italic>
<sup>2</sup>. Since the Fisher's exact test has its own special nature, there is no statistical value.</p></fn><fn id="os70113-note-0004"><p>Abbreviations: BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CRP, C&#8208;reactive protein; FBG, fasting blood glucose; HB, hemoglobin; IL&#8208;6, interleukin&#8208;6; Preop, preoperative; VAS, visual analog score.</p></fn></table-wrap-foot></table-wrap></sec><sec id="os70113-sec-0013"><label>3.2</label><title>The Radiological Data of a Representative Patient</title><p>To enhance the readers' understanding of our work, we present radiological data from a representative patient who underwent revision THA. This 49&#8208;year&#8208;old female developed left hip pain 10&#8201;years after primary THA. She was diagnosed with prosthetic loosening, polyethylene liner wear, and osteolytic defects and subsequently underwent revision surgery at our hospital. The procedure included prosthesis removal, total hip revision, and allograft bone grafting. Postoperative and final follow&#8208;up evaluations demonstrated stable fixation of the revised hip components, with no evidence of loosening or infection. The acetabular cup and femoral stem remained securely embedded in a satisfactory position (Figure&#160;<xref rid="os70113-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="os70113-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Radiographs of a 49&#8208;year&#8208;old woman with prosthetic loosening, polyethylene liner wear, and osteolytic defects who underwent revision THA: (A and B) Preoperative anteroposterior of pelvis and oblique radiographs of femur neck; (C and D) Anteroposterior of pelvis and oblique radiographs of femur neck at 1 week after surgery; (E and F) Anteroposterior of pelvis and oblique radiographs of femur neck at 1&#8208;year follow up.</p></caption><graphic position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="OS-17-2570-g005.jpg"/></fig></sec><sec id="os70113-sec-0014"><label>3.3</label><title>Pain Level and Analgesic Rescue</title><p>Postoperative dynamic pain levels, as measured by VAS scores, are shown in Figure&#160;<xref rid="os70113-fig-0002" ref-type="fig">2</xref>. Patients in the dexamethasone group reported significantly lower VAS scores on PODs 1, 2, and 3 compared to the control group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests). However, no significant differences were observed on PODs 15 and 90 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.215 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.364, respectively, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests). Consistent with these findings, the number of patients requiring morphine for pain relief was significantly lower in the dexamethasone group than in the control group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.033, chi&#8208;square test). Similarly, total morphine consumption was reduced in the dexamethasone group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000, Mann&#8211;Whitney <italic toggle="yes">U</italic> test; Table&#160;<xref rid="os70113-tbl-0002" ref-type="table">2</xref>).</p><fig position="float" fig-type="FIGURE" id="os70113-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>The VAS level of dynamic pain in the dexamethasone group and control group. VAS scores in the dexamethasone group were significantly lower than those in the control group on PODs 1, 2, and 3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests), with no differences noted on PODs 15 and 90 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.215 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.364, respectively, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. Pre&#8208;op, preoperative; VAS, visual analog scale. POD1, 2, 3, 15, and 90: 1, 2, 3, 15, and 90&#8201;days postoperatively, respectively.</p></caption><graphic position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="OS-17-2570-g003.jpg"/></fig><table-wrap position="float" id="os70113-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>The requirement of rescue treatment among the 2 groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group (<italic toggle="yes">n</italic>&#8201;=&#8201;196)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dexa group, (<italic toggle="yes">n</italic>&#8201;=&#8201;218)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Statistical value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" rowspan="1">Morphine</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Number <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">77 (39.29)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (29.36)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;4.503</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total dose (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">1595</td><td align="center" valign="top" rowspan="1" colspan="1">989</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;5.021</td><td align="center" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Metoclopramide</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Number <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (20.92)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (11.47)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;6.872</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total dose (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">620</td><td align="center" valign="top" rowspan="1" colspan="1">300</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;2.139</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Ondansetron</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Number <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (31.63)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (20.18)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;7.098</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total dose (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">309</td><td align="center" valign="top" rowspan="1" colspan="1">187</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;2.539</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td></tr></tbody></table><table-wrap-foot id="os70113-ntgp-0003"><fn id="os70113-note-0005"><p>
<italic toggle="yes">Note</italic>: Regarding statistical value, for the independent samples <italic toggle="yes">t</italic>&#8208;test, the results are presented as <italic toggle="yes">t</italic>&#8208;values; for the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, the results are shown as <italic toggle="yes">Z</italic>&#8208;values; for the chi&#8208;square test, the results are represented by <italic toggle="yes">X</italic>
<sup>2</sup>. Since the Fisher's exact test has its own special nature, there is no statistical value.</p></fn></table-wrap-foot></table-wrap></sec><sec id="os70113-sec-0015"><label>3.4</label><title>Inflammation Markers</title><p>Acute inflammation markers (CRP and IL&#8208;6) were elevated in all patients on POD 15 compared to baseline levels. Systemic CRP levels are shown in Figure&#160;<xref rid="os70113-fig-0003" ref-type="fig">3</xref>, and systemic IL&#8208;6 levels in Figure&#160;<xref rid="os70113-fig-0004" ref-type="fig">4</xref>. CRP levels in the dexamethasone group were significantly lower than those in the control group on PODs 1, 2, and 3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, <italic toggle="yes">t</italic>&#8208;tests), with no differences noted on POD 15 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.829, <italic toggle="yes">t</italic>&#8208;test). Similarly, IL&#8208;6 levels were significantly lower in the dexamethasone group on PODs 1, 2, 3, and 15 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, <italic toggle="yes">t</italic>&#8208;tests).</p><fig position="float" fig-type="FIGURE" id="os70113-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>The level of CRP in the dexamethasone group and control group. CRP levels in the dexamethasone group were significantly lower than those in the control group on PODs 1, 2, and 3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, <italic toggle="yes">t</italic>&#8208;tests), with no differences noted on POD 15 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.829, <italic toggle="yes">t</italic>&#8208;test). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. CRP, C&#8208;reactive protein; Pre&#8208;op, preoperative. POD1, 2, 3, and 15: 1, 2, 3, and 15&#8201;days postoperatively, respectively.</p></caption><graphic position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="OS-17-2570-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="os70113-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>The level of IL&#8208;6 in the dexamethasone group and control group. IL&#8208;6 levels were significantly lower in the dexamethasone group on PODs 1, 2, 3, and 15 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.000 for all comparisons, <italic toggle="yes">t</italic>&#8208;tests). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. IL&#8208;6, interleukin&#8208;6; Pre&#8208;op, preoperative. POD1, 2, 3, and 15: 1, 2, 3, and 15&#8201;days postoperatively, respectively.</p></caption><graphic position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="OS-17-2570-g002.jpg"/></fig></sec><sec id="os70113-sec-0016"><label>3.5</label><title>
<styled-content style="fixed-case" toggle="no">PONV</styled-content> and Antiemetic Rescue</title><p>As shown in Table&#160;<xref rid="os70113-tbl-0003" ref-type="table">3</xref>, the incidence of PONV was significantly lower in the dexamethasone group compared to the control group during hospitalization (<italic toggle="yes">p</italic>&#8201;=&#8201;0.008, chi&#8208;square test). Accordingly, fewer patients in the dexamethasone group required antiemetic rescue medications, including metoclopramide and ondansetron (<italic toggle="yes">p</italic>&#8201;=&#8201;0.009 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.008, respectively, chi&#8208;square tests). The total consumption of both metoclopramide and ondansetron was also significantly lower in the dexamethasone group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.033 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.011, respectively, Mann&#8211;Whitney <italic toggle="yes">U</italic> tests; Table&#160;<xref rid="os70113-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="os70113-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>LOS, PONV, complications, and 30&#8208;day readmission rate among the 2 Groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group, (<italic toggle="yes">n</italic>&#8201;=&#8201;196)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dexa group, (<italic toggle="yes">n</italic>&#8201;=&#8201;218)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Statistical value</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">LOS (d)</td><td align="center" valign="top" rowspan="1" colspan="1">8.65&#8201;&#177;&#8201;3.36</td><td align="center" valign="top" rowspan="1" colspan="1">8.28&#8201;&#177;&#8201;2.83</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8201;=&#8201;1.168</td><td align="center" valign="top" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PONV <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (40.81)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (28.4)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;7.024</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">FBG</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">POD1</td><td align="center" valign="top" rowspan="1" colspan="1">6.88 (0.94)</td><td align="center" valign="top" rowspan="1" colspan="1">6.76 (0.85)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;0.087</td><td align="center" valign="top" rowspan="1" colspan="1">0.991</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">POD3</td><td align="center" valign="top" rowspan="1" colspan="1">5.38 (0.93)</td><td align="center" valign="top" rowspan="1" colspan="1">5.29 (0.86)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Z</italic>&#8201;=&#8201;&#8208;0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.972</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Periprosthetic joint infection <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.02)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.915</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aseptic failure <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.02)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.37)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dislocation <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.02)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.37)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#8208;day readmission rate <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (3.06)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3.70)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8201;=&#8201;0.130</td><td align="center" valign="top" rowspan="1" colspan="1">0.732</td></tr></tbody></table><table-wrap-foot id="os70113-ntgp-0004"><fn id="os70113-note-0006"><p>
<italic toggle="yes">Note</italic>: For non&#8208;normally distributed data, we describe them using the median (interquartile range, IQR). Regarding statistical value, for the independent samples <italic toggle="yes">t</italic>&#8208;test, the results are presented as <italic toggle="yes">t</italic>&#8208;values; for the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, the results are shown as <italic toggle="yes">Z</italic>&#8208;values; for the chi&#8208;square test, the results are represented by <italic toggle="yes">X</italic>
<sup>2</sup>. Since the Fisher's exact test has its own special nature, there is no statistical value.</p></fn><fn id="os70113-note-0007"><p>Abbreviations: FBG, fasting blood glucose; LOS, length of stay; PONV, postoperative nausea and vomiting.</p></fn></table-wrap-foot></table-wrap></sec><sec id="os70113-sec-0017"><label>3.6</label><title>
<styled-content style="fixed-case" toggle="no">LOS</styled-content> and Complications</title><p>LOS and complications are shown in Table&#160;<xref rid="os70113-tbl-0003" ref-type="table">3</xref>. No significant differences were observed in hospital LOS between the dexamethasone and control groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.251, <italic toggle="yes">t</italic>&#8208;test). Similarly, there were no differences in the incidence of complications, including periprosthetic joint infection, aseptic failure, or dislocation (<italic toggle="yes">p</italic>&#8201;=&#8201;0.915, <italic toggle="yes">p</italic>&#8201;=&#8201;0.741, and <italic toggle="yes">p</italic>&#8201;=&#8201;0.741, respectively, Fisher's exact tests). It is particularly noteworthy that in both the dexamethasone group and the control group, whether patients had diabetes did not significantly affect the rate of periprosthetic joint infection (<italic toggle="yes">p</italic>&#8201;=&#8201;1.000 and <italic toggle="yes">p</italic>&#8201;=&#8201;1.000, respectively, from Fisher's exact test). Furthermore, there was also no significant difference in FBG on POD1 and POD3 between the two groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.991 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.971, respectively from Fisher's exact test). The 30&#8208;day readmission rate also did not differ significantly between groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.732, Fisher's exact test).</p></sec></sec><sec sec-type="discussion" id="os70113-sec-0018"><label>4</label><title>Discussion</title><sec id="os70113-sec-0019"><label>4.1</label><title>The Main Findings and Significance of the Study</title><p>This study is the first to demonstrate that perioperative dexamethasone administration in aseptic revision hip arthroplasty effectively alleviates postoperative pain, reduces PONV, and controls inflammation without increasing risks of surgical&#8208;site infections or dislocation. The findings provide novel clinical evidence and practical guidance for dexamethasone use in revision joint surgeries.</p></sec><sec id="os70113-sec-0020"><label>4.2</label><title>The Efficacy of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty</title><p>Consistent with prior research in total joint arthroplasty, our results confirm the efficacy of dexamethasone in controlling inflammation, reducing postoperative pain, and analgesic use during aseptic revision hip arthroplasty. The analgesic and anti&#8208;inflammatory effects varied with dosage and frequency. For instance, a single dose of 40&#8201;mg dexamethasone has been proved to relieve dynamic pain within 24&#8201;h and reduce CRP levels at 48&#8201;h [<xref rid="os70113-bib-0012" ref-type="bibr">12</xref>]. Besides, an additional dose of dexamethasone to anesthetic induction at 8&#8201;h postoperatively significantly reduced pain and tramadol consumption after primary THA, indicating the repeated doses of dexamethasone may enhance pain control [<xref rid="os70113-bib-0008" ref-type="bibr">8</xref>]. Moreover, a study examining the frequency of dexamethasone administration found that patients on a 3&#8208;dose regimen had the lowest dynamic pain scores on POD3, indicating that frequent dexamethasone use may improve its analgesic and anti&#8208;inflammatory efficacy [<xref rid="os70113-bib-0013" ref-type="bibr">13</xref>, <xref rid="os70113-bib-0014" ref-type="bibr">14</xref>, <xref rid="os70113-bib-0015" ref-type="bibr">15</xref>]. In the dexamethasone group of our study, 119 patients received a single dose of dexamethasone averaging 8.99&#8201;mg, 58 patients received two doses of dexamethasone averaging 7.53&#8201;mg, and 18 patients received three doses of dexamethasone averaging 7.48&#8201;mg. Although most patients undergoing aseptic revision arthroplasty received only a single low dose of dexamethasone, its significant effectiveness in controlling pain and reducing analgesic consumption has been strongly validated, providing a data reference for future clinical studies on the dosing frequency of dexamethasone. Other studies have explored the impact of different dosages of dexamethasone. For instance, a meta&#8208;analysis of 11 trials suggested that high&#8208;dose dexamethasone are more effective than low doses in reducing acute postoperative pain and controlling inflammation within 24&#8201;h [<xref rid="os70113-bib-0016" ref-type="bibr">16</xref>]. Similarly, in a double&#8208;blind, randomized control trial, the addition of 8&#8201;mg dexamethasone did not reduce 24h morphine consumption, proving the conclusion above [<xref rid="os70113-bib-0017" ref-type="bibr">17</xref>]. However, some scientists observed no difference in resting pain between the dexamethasone (40&#8201;mg) group and the control group at either time period [<xref rid="os70113-bib-0018" ref-type="bibr">18</xref>]. In our study, patients in the dexamethasone group received an average intravenous injection of 12.67&#8201;mg of dexamethasone, suggesting that small doses of dexamethasone may also benefit patients. However, due to limited research on dexamethasone in hip revision arthroplasty, further prospective investigation is needed to determine the optimal dosage, frequency of administration, and possible combination therapy.</p><p>Apart from post operative pain, PONV is another common adverse event after THA, which can lead to delayed discharge and hinder functional recovery [<xref rid="os70113-bib-0019" ref-type="bibr">19</xref>]. A single low dose of dexamethasone is commonly given preoperatively to reduce PONV [<xref rid="os70113-bib-0020" ref-type="bibr">20</xref>]. Previous studies have well demonstrated the antiemetic efficacy of dexamethasone, with its mechanism of action effectively inhibiting prostaglandin synthesis or endogenous opioid release [<xref rid="os70113-bib-0021" ref-type="bibr">21</xref>, <xref rid="os70113-bib-0022" ref-type="bibr">22</xref>]. The use of low&#8208;dose dexamethasone during the THA perioperative period can effectively reduce postoperative nausea of inflammatory origin [<xref rid="os70113-bib-0023" ref-type="bibr">23</xref>]. However, the sensation of nausea, considered an unpleasant subjective experience, may persist for several days post&#8208;surgery, prompting discussions on the potential benefits of multiple doses [<xref rid="os70113-bib-0024" ref-type="bibr">24</xref>, <xref rid="os70113-bib-0025" ref-type="bibr">25</xref>]. In a prospective randomized controlled trial, patients receiving two doses of dexamethasone exhibited a lower incidence of PONV and reduced use of antiemetics compared to those receiving a single dose [<xref rid="os70113-bib-0008" ref-type="bibr">8</xref>]. Another trial showed that administering two low doses of perioperative dexamethasone to patients can significantly control nausea as well [<xref rid="os70113-bib-0007" ref-type="bibr">7</xref>]. In the current study, low&#8208;dose dexamethasone was shown to reduce PONV and the need for antiemetic drugs in revision hip arthroplasty, consistent with the findings of recent studies. Overall, the perioperative addition of dexamethasone may offer an effective strategy for managing PONV [<xref rid="os70113-bib-0026" ref-type="bibr">26</xref>].</p></sec><sec id="os70113-sec-0021"><label>4.3</label><title>The Adverse Events of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty</title><p>While the efficacy of dexamethasone has been extensively evaluated, its potential adverse events, including postoperative infection, dislocation, and hyperglycemia, should not be overlooked. Periprosthetic joint infection is a significant complication of THA [<xref rid="os70113-bib-0025" ref-type="bibr">25</xref>]. However, evidence indicates that dexamethasone, despite its immunosuppressive effects, is not linked to an increased risk of infectious complications [<xref rid="os70113-bib-0027" ref-type="bibr">27</xref>]. Researchers observed similar rates of periprosthetic joint infection at the 90&#8208;day follow&#8208;up between the dexamethasone group and the control group (0.3% vs. 0.7%, <italic toggle="yes">p&#8201;=</italic>&#8201;0.126) [<xref rid="os70113-bib-0028" ref-type="bibr">28</xref>]. In addition, the impact of dexamethasone on glucose levels has been particularly evaluated in diabetic patients undergoing total joint arthroplasty, as dexamethasone is known to induce hyperglycemia, theoretically associated with higher infection rates. However, while a significant positive correlation was found between dexamethasone administration and fasting blood glucose levels on POD1, as well as a significant association between POD1 glucose levels and the likelihood of postoperative infection, interaction analyses revealed no substantial increase in the risk of infectious outcomes when comparing patients with and without perioperative dexamethasone administration [<xref rid="os70113-bib-0025" ref-type="bibr">25</xref>]. Thus, scientists agree that dexamethasone should not be withheld, as its benefits seem to outweigh the risks even in patients with diabetes [<xref rid="os70113-bib-0029" ref-type="bibr">29</xref>, <xref rid="os70113-bib-0030" ref-type="bibr">30</xref>]. Although most studies demonstrate that transient changes in glucose were unlikely to be of clinical significance, some trials posted controversial results [<xref rid="os70113-bib-0031" ref-type="bibr">31</xref>]. In diabetic patients, additional dexamethasone control of PONV in those undergoing THA had a negative impact on glycemic control specifically in those with poorly controlled diabetes and should be avoided [<xref rid="os70113-bib-0032" ref-type="bibr">32</xref>]. Our study has evaluated the safety of dexamethasone in aseptic revision hip arthroplasty by examining rates of post&#8208;infection, readmission, and dislocation, revealing no differences between the two study groups, supporting previous research findings.</p></sec><sec id="os70113-sec-0022"><label>4.4</label><title>Timing of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty</title><p>Multiple studies have investigated the correlation between dexamethasone administration timing and postoperative outcomes. For preoperative single&#8208;dose administration, a study on THA showed that a single intravenous dose of 40&#8201;mg dexamethasone preoperatively exerts a prolonged suppressive effect on the inflammatory response and significantly reduces dynamic pain at 24&#8201;h postoperatively [<xref rid="os70113-bib-0012" ref-type="bibr">12</xref>]. However, in diabetic patients, preoperative dexamethasone use for controlling PONV during elective total knee/hip arthroplasty has been associated with adverse effects on glycemic control [<xref rid="os70113-bib-0032" ref-type="bibr">32</xref>]. Regarding postoperative additional dosing, research indicates that in primary THA patients receiving a preoperative single dose, an additional 8&#8208;h postoperative dexamethasone dose further alleviates pain, reduces tramadol consumption, shortens the time to first ambulation, and decreases hospital LOS [<xref rid="os70113-bib-0013" ref-type="bibr">13</xref>]. For perioperative combined administration, a randomized controlled trial confirmed that elective THA patients receiving 8&#8201;mg intravenous dexamethasone at anesthesia induction and 24&#8201;h postoperatively demonstrate significantly accelerated discharge readiness, primarily through reduced postoperative pain scores and morphine requirements [<xref rid="os70113-bib-0006" ref-type="bibr">6</xref>]. Another study showed that a split&#8208;dose regimen (preoperative and postoperative administration) outperforms single high&#8208;dose administration in reducing pain and inflammation, increasing range of motion and improving patient satisfaction [<xref rid="os70113-bib-0033" ref-type="bibr">33</xref>]. Although some of the above studies focused on the timing of dexamethasone administration and its correlation with patient outcomes, existing studies on dexamethasone administration timing are scarce, primarily due to vague clinical definitions of perioperative timing, limitations of retrospective research, and a focus on dosage/frequency rather than timing. Thus, future prospective studies are warranted to investigate the timing of dexamethasone administration and its correlation with patient outcomes.</p></sec><sec id="os70113-sec-0023"><label>4.5</label><title>Strengths and Limitations of This Study</title><p>This study, for the first time with a relatively large sample size, confirms that perioperative dexamethasone administration in aseptic revision hip arthroplasty can effectively alleviate postoperative pain, reduce PONV, control inflammation, and does not increase the risks of surgical&#8208;site infection, dislocation, or hyperglycemia. The study has conducted a comprehensive evaluation of the safety and efficacy of dexamethasone, providing reliable evidence for clinical practice and further research. However, several limitations must be acknowledged in this study: (1) The retrospective design and nonrandomized nature may affect the validity of the findings; (2) The lack of patient blinding could introduce bias in outcome assessment; (3) VAS scores were not consistently assessed by the same therapist, leading to potential interobserver variability. Further research involving a larger number of patients and centers is warranted. Even so, our findings provide a foundation for the clinical application of dexamethasone and future investigations.</p></sec></sec><sec sec-type="conclusions" id="os70113-sec-0024"><label>5</label><title>Conclusions</title><p>The administration of dexamethasone in patients undergoing aseptic revision hip arthroplasty can alleviate postoperative pain, prevent PONV, and control inflammation. Additionally, dexamethasone treatment reduces the number of patients needing rescue medication for nausea and vomiting as well as pain and decreases the overall consumption of related drugs. However, more prospective studies are still needed to evaluate the safety and efficacy of dexamethasone in patients undergoing revision arthroplasty.</p></sec><sec id="os70113-sec-0029"><title>Author Contributions</title><p>Qiyu Y. Xie and Zhixin X. Liao applied for ethical clearance and registered this study, drafted the work, and revised it critically for important intellectual content. Hong Xu, Wei Yao, Xuming M. Chen, and Xufeng F. Wan. collected data, analyzed, and interpreted data for the work. Duan Wang and Zongke K. Zhou contributed to the conception and design of the work, participated in the final approval of the version to be published, and revised the manuscript.</p></sec><sec sec-type="COI-statement" id="os70113-sec-0028"><title>Disclosure</title><p>No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. This study was funded by National Key Research and Development Program of China (No. 2022YFC2503100, 2022YFC2503104, and 2022YFC2503103), the National Natural Science Foundation of China (82402773), as well as West China Hospital of Sichuan University 1&#183;3&#183;5 Discipline Excellence Development Project ZYAI24023, ZYGD23033.</p><p>Authors declaration: The manuscript has been read and approved by all the authors. The requirements for authorship according to the latest guidelines of the International Committee of Medical Journal Editors have been met, and each author believes that the manuscript represents honest work.</p></sec><sec id="os70113-sec-0025"><title>Ethics Statement</title><p>The Ethics Committee of West China Hospital of Sichuan University approved the study (approval no. 2024&#8211;1789). Written informed consent was deemed unnecessary by the hospital's institutional review board.</p></sec><sec sec-type="COI-statement" id="os70113-sec-0026"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="os70113-sec-0027"><title>Acknowledgments</title><p>We would like to thank the relevant staff for guidance, support, and collaboration in our hospital.</p></ack><ref-list content-type="cited-references" id="os70113-bibl-0001"><title>References</title><ref id="os70113-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="os70113-cit-0001"><string-name name-style="western"><given-names>F.</given-names><surname>Falez</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Papalia</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Favetti</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Panegrossi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Casella</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Mazzotta</surname></string-name>, &#8220;<article-title>Total Hip Arthroplasty Instability in Italy</article-title>,&#8221; <source>International Orthopaedics</source><volume>41</volume>, no. <issue>3</issue> (<year>2017</year>): <fpage>635</fpage>&#8211;<lpage>644</lpage>.<pub-id pub-id-type="pmid">27999925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00264-016-3345-6</pub-id></mixed-citation></ref><ref id="os70113-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="os70113-cit-0002"><string-name name-style="western"><given-names>M.</given-names><surname>Lu</surname></string-name> and <string-name name-style="western"><given-names>D.</given-names><surname>Phillips</surname></string-name>, &#8220;<article-title>Total Hip Arthroplasty for Posttraumatic Conditions</article-title>,&#8221; <source>Journal of the American Academy of Orthopaedic Surgeons</source><volume>27</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>275</fpage>&#8211;<lpage>285</lpage>.<pub-id pub-id-type="pmid">30289797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5435/JAAOS-D-17-00775</pub-id></mixed-citation></ref><ref id="os70113-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="os70113-cit-0003"><string-name name-style="western"><given-names>M.</given-names><surname>Loppini</surname></string-name>, <string-name name-style="western"><given-names>F. M.</given-names><surname>Gambaro</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>di Maio</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Grappiolo</surname></string-name>, &#8220;<article-title>Femoral Bone Defect Classifications in Revision Total Hip Arthroplasty: A Comprehensive Review and Proposal of a New Algorithm of Management</article-title>,&#8221; <source>EFORT Open Rev</source><volume>9</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>160</fpage>&#8211;<lpage>172</lpage>.<pub-id pub-id-type="pmid">38457928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EOR-21-0088</pub-id><pub-id pub-id-type="pmcid">PMC10958244</pub-id></mixed-citation></ref><ref id="os70113-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="os70113-cit-0004"><string-name name-style="western"><given-names>A. K.</given-names><surname>Sorial</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Anjum</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Cook</surname></string-name>, <string-name name-style="western"><given-names>T. N.</given-names><surname>Board</surname></string-name>, and <string-name name-style="western"><given-names>T. W.</given-names><surname>O'Neill</surname></string-name>, &#8220;<article-title>Statins, Bone Biology and Revision Arthroplasty: Review of Clinical and Experimental Evidence</article-title>,&#8221; <source>Therapeutic Advances in Musculoskeletal Disease</source><volume>12</volume> (<year>2020</year>): <elocation-id>1759720&#215;20966229</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1759720X20966229</pub-id><pub-id pub-id-type="pmcid">PMC7747105</pub-id><pub-id pub-id-type="pmid">33403020</pub-id></mixed-citation></ref><ref id="os70113-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="os70113-cit-0005"><string-name name-style="western"><given-names>J.</given-names><surname>Arraut</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>C. T.</given-names><surname>Oakley</surname></string-name>, <string-name name-style="western"><given-names>O. S.</given-names><surname>Barzideh</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Rozell</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Schwarzkopf</surname></string-name>, &#8220;<article-title>The AAHKS Best Podium Presentation Research Award: A Second Dose of Dexamethasone Reduces Postoperative Opioid Consumption and Pain in Total Joint Arthroplasty</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>38</volume>, no. <issue>7 Suppl 2</issue> (<year>2023</year>): <fpage>S21</fpage>&#8211;<lpage>S28</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2023.02.007</pub-id><pub-id pub-id-type="pmid">36775214</pub-id></mixed-citation></ref><ref id="os70113-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="os70113-cit-0006"><string-name name-style="western"><given-names>R.</given-names><surname>Dissanayake</surname></string-name>, <string-name name-style="western"><given-names>H. N.</given-names><surname>Du</surname></string-name>, <string-name name-style="western"><given-names>I. K.</given-names><surname>Robertson</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ogden</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Wiltshire</surname></string-name>, and <string-name name-style="western"><given-names>J. S.</given-names><surname>Mulford</surname></string-name>, &#8220;<article-title>Does Dexamethasone Reduce Hospital Readiness for Discharge, Pain, Nausea, and Early Patient Satisfaction in Hip and Knee Arthroplasty? A Randomized, Controlled Trial</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>33</volume>, no. <issue>11</issue> (<year>2018</year>): <fpage>3429</fpage>&#8211;<lpage>3436</lpage>.<pub-id pub-id-type="pmid">30078660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2018.07.013</pub-id></mixed-citation></ref><ref id="os70113-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="os70113-cit-0007"><string-name name-style="western"><given-names>Y.&#8208;T.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>X.&#8208;W.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;W.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>F.&#8208;X.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>The Efficacy and Safety of Two Low&#8208;Dose Peri&#8208;Operative Dexamethasone on Pain and Recovery Following Total Hip Arthroplasty: A Randomized Controlled Trial</article-title>,&#8221; <source>International Orthopaedics</source><volume>42</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>499</fpage>&#8211;<lpage>505</lpage>.<pub-id pub-id-type="pmid">28647788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00264-017-3537-8</pub-id></mixed-citation></ref><ref id="os70113-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="os70113-cit-0008"><string-name name-style="western"><given-names>C. M.</given-names><surname>Lucero</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Garc&#237;a&#8208;Mansilla</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Zanotti</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Comba</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Slullitel</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Buttaro</surname></string-name>, &#8220;<article-title>A Repeat Dose of Perioperative Dexamethasone Can Effectively Reduce Pain, Opioid Requirement, Time to Ambulation, and In&#8208;Hospital Stay After Total Hip Arthroplasty: A Prospective Randomized Controlled Trial</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>36</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>3938</fpage>&#8211;<lpage>3944</lpage>.<pub-id pub-id-type="pmid">34538546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2021.08.020</pub-id></mixed-citation></ref><ref id="os70113-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="os70113-cit-0009"><string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Cao</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>Multiple Doses of Perioperative Dexamethasone Further Improve Clinical Outcomes After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Study</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>33</volume>, no. <issue>11</issue> (<year>2018</year>): <fpage>3448</fpage>&#8211;<lpage>3454</lpage>.<pub-id pub-id-type="pmid">30033064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2018.06.031</pub-id></mixed-citation></ref><ref id="os70113-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="os70113-cit-0010"><string-name name-style="western"><given-names>M. E.</given-names><surname>Kelly</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Turcotte</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Aja</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>MacDonald</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>King</surname></string-name>, &#8220;<article-title>Impact of Dexamethasone on Length of Stay and Early Pain Control in Direct Anterior Approach Total Hip Arthroplasty With Neuraxial Anesthesia</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>36</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>1009</fpage>&#8211;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">33012598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2020.09.015</pub-id></mixed-citation></ref><ref id="os70113-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="os70113-cit-0011"><string-name name-style="western"><given-names>Y.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Cao</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>Multiple Low&#8208;Dose Dexamethasone Further Improves Clinical Outcomes Following Total Hip Arthroplasty</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>33</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>1426</fpage>&#8211;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">29258763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2017.11.057</pub-id></mixed-citation></ref><ref id="os70113-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="os70113-cit-0012"><string-name name-style="western"><given-names>K. J.</given-names><surname>Kardash</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Sarrazin</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Tessler</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>Velly</surname></string-name>, &#8220;<article-title>Single&#8208;Dose Dexamethasone Reduces Dynamic Pain After Total Hip Arthroplasty</article-title>,&#8221; <source>Anesthesia and Analgesia</source><volume>106</volume>, no. <issue>4</issue> (<year>2008</year>): <fpage>1253</fpage>.<pub-id pub-id-type="pmid">18349202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e318164f319</pub-id></mixed-citation></ref><ref id="os70113-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="os70113-cit-0013"><string-name name-style="western"><given-names>Y.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>Repeat Doses of Dexamethasone up to 48 Hours Further Reduce Pain and Inflammation After Total Hip Arthroplasty: A Randomized Controlled Trial</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>35</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>3223</fpage>&#8211;<lpage>3229</lpage>.<pub-id pub-id-type="pmid">32636109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2020.06.023</pub-id></mixed-citation></ref><ref id="os70113-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="os70113-cit-0014"><string-name name-style="western"><given-names>F. L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>B. C.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>W. W.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Yin</surname></string-name>, &#8220;<article-title>Different Dexamethasone Doses in the Perioperative Period Improve Short&#8208;Term Outcomes of Total Hip Arthroplasty: A Randomized Controlled Trial</article-title>,&#8221; <source>European Review for Medical and Pharmacological Sciences</source><volume>27</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>3438</fpage>&#8211;<lpage>3447</lpage>.<pub-id pub-id-type="pmid">37140293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202304_32114</pub-id></mixed-citation></ref><ref id="os70113-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="os70113-cit-0015"><string-name name-style="western"><given-names>D.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Xue</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Liu</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>What Is the Optimal Regimen for Intravenous Dexamethasone Administration in Primary Total Hip Arthroplasty?: A Protocol of Randomized Controlled Trial</article-title>,&#8221; <source>Medicine (Baltimore)</source><volume>99</volume>, no. <issue>36</issue> (<year>2020</year>): <elocation-id>e22070</elocation-id>.<pub-id pub-id-type="pmid">32899074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000022070</pub-id><pub-id pub-id-type="pmcid">PMC7478557</pub-id></mixed-citation></ref><ref id="os70113-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="os70113-cit-0016"><string-name name-style="western"><given-names>C.</given-names><surname>Yue</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Wei</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, &#8220;<article-title>Perioperative Systemic Steroid for Rapid Recovery in Total Knee and Hip Arthroplasty: A Systematic Review and Meta&#8208;Analysis of Randomized Trials</article-title>,&#8221; <source>Journal of Orthopaedic Surgery and Research</source><volume>12</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>100</fpage>.<pub-id pub-id-type="pmid">28655354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13018-017-0601-4</pub-id><pub-id pub-id-type="pmcid">PMC5488481</pub-id></mixed-citation></ref><ref id="os70113-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="os70113-cit-0017"><string-name name-style="western"><given-names>K.</given-names><surname>El&#8208;Boghdadly</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Short</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Gandhi</surname></string-name>, and <string-name name-style="western"><given-names>V. W. S.</given-names><surname>Chan</surname></string-name>, &#8220;<article-title>Addition of Dexamethasone to Local Infiltration Analgesia in Elective Total Hip Arthroplasty: A Double&#8208;Blind, Randomized Control Trial</article-title>,&#8221; <source>Regional Anesthesia and Pain Medicine</source><volume>44</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>1003</fpage>&#8211;<lpage>1009</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/rapm-2019-100873</pub-id><pub-id pub-id-type="pmid">31563881</pub-id></mixed-citation></ref><ref id="os70113-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="os70113-cit-0018"><string-name name-style="western"><given-names>S. G.</given-names><surname>Bergeron</surname></string-name>, <string-name name-style="western"><given-names>K. J.</given-names><surname>Kardash</surname></string-name>, <string-name name-style="western"><given-names>O. L.</given-names><surname>Huk</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Zukor</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Antoniou</surname></string-name>, &#8220;<article-title>Perioperative Dexamethasone Does Not Affect Functional Outcome in Total Hip Arthroplasty</article-title>,&#8221; <source>Clinical Orthopaedics and Related Research</source><volume>467</volume>, no. <issue>6</issue> (<year>2009</year>): <fpage>1463</fpage>&#8211;<lpage>1467</lpage>.<pub-id pub-id-type="pmid">19224304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11999-009-0733-x</pub-id><pub-id pub-id-type="pmcid">PMC2674173</pub-id></mixed-citation></ref><ref id="os70113-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="os70113-cit-0019"><string-name name-style="western"><given-names>X.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>P. F.</given-names><surname>White</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Ma</surname></string-name>, &#8220;<article-title>An Update on the Management of Postoperative Nausea and Vomiting</article-title>,&#8221; <source>Journal of Anesthesia</source><volume>31</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>617</fpage>&#8211;<lpage>626</lpage>.<pub-id pub-id-type="pmid">28455599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00540-017-2363-x</pub-id></mixed-citation></ref><ref id="os70113-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="os70113-cit-0020"><string-name name-style="western"><given-names>G. S.</given-names><surname>De Oliveira</surname>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Almeida</surname></string-name>, <string-name name-style="western"><given-names>H. T.</given-names><surname>Benzon</surname></string-name>, and <string-name name-style="western"><given-names>R. J.</given-names><surname>McCarthy</surname></string-name>, &#8220;<article-title>Perioperative Single Dose Systemic Dexamethasone for Postoperative Pain: A Meta&#8208;Analysis of Randomized Controlled Trials</article-title>,&#8221; <source>Anesthesiology</source><volume>115</volume>, no. <issue>3</issue> (<year>2011</year>): <fpage>575</fpage>&#8211;<lpage>588</lpage>.<pub-id pub-id-type="pmid">21799397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e31822a24c2</pub-id></mixed-citation></ref><ref id="os70113-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="os70113-cit-0021"><string-name name-style="western"><given-names>I. J.</given-names><surname>Koh</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>Y. T.</given-names><surname>Jeon</surname></string-name>, and <string-name name-style="western"><given-names>T. K.</given-names><surname>Kim</surname></string-name>, &#8220;<article-title>Preemptive Low&#8208;Dose Dexamethasone Reduces Postoperative Emesis and Pain After TKA: A Randomized Controlled Study</article-title>,&#8221; <source>Clinical Orthopaedics and Related Research</source><volume>471</volume>, no. <issue>9</issue> (<year>2013</year>): <fpage>3010</fpage>&#8211;<lpage>3020</lpage>.<pub-id pub-id-type="pmid">23645340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11999-013-3032-5</pub-id><pub-id pub-id-type="pmcid">PMC3734432</pub-id></mixed-citation></ref><ref id="os70113-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="os70113-cit-0022"><string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>Dexamethasone Attenuates the Perioperative Acute Phase Response for Simultaneous Bilateral Total Hip Arthroplasty</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>37</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>888</fpage>&#8211;<lpage>891</lpage>.<pub-id pub-id-type="pmid">35031417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2022.01.010</pub-id></mixed-citation></ref><ref id="os70113-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="os70113-cit-0023"><string-name name-style="western"><given-names>Y.</given-names><surname>Mo</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Yin</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Efficacy of Dexamethasone in Reducing Pain and Inflammation and Accelerating Total Hip Arthroplasty Postoperative Recovery: A Randomized Controlled Trial</article-title>,&#8221; <source>Journal of Perianesthesia Nursing</source><volume>39</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>589</fpage>&#8211;<lpage>595</lpage>.<pub-id pub-id-type="pmid">38219078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jopan.2023.10.022</pub-id></mixed-citation></ref><ref id="os70113-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="os70113-cit-0024"><string-name name-style="western"><given-names>Y.</given-names><surname>Miyagawa</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ejiri</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kuzuya</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Osada</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ishiguro</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Yamada</surname></string-name>, &#8220;<article-title>Methylprednisolone Reduces Postoperative Nausea in Total Knee and Hip Arthroplasty</article-title>,&#8221; <source>Journal of Clinical Pharmacy and Therapeutics</source><volume>35</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>679</fpage>&#8211;<lpage>684</lpage>.<pub-id pub-id-type="pmid">21054459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2710.2009.01141.x</pub-id></mixed-citation></ref><ref id="os70113-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="os70113-cit-0025"><string-name name-style="western"><given-names>I. A.</given-names><surname>Jones</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wier</surname></string-name>, <string-name name-style="western"><given-names>K. C.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Dexamethasone&#8208;Associated Hyperglycemia Is Not Associated With Infectious Complications After Total Joint Arthroplasty in Diabetic Patients</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>39</volume>, no. <issue>8S1</issue> (<year>2024</year>): <fpage>S43</fpage>&#8211;<lpage>S52</lpage>.<pub-id pub-id-type="pmid">38220028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2024.01.025</pub-id></mixed-citation></ref><ref id="os70113-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="os70113-cit-0026"><string-name name-style="western"><given-names>F. P.</given-names><surname>Bustos</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>Coobs</surname></string-name>, and <string-name name-style="western"><given-names>J. T.</given-names><surname>Moskal</surname></string-name>, &#8220;<article-title>A Retrospective Analysis of the Use of Intravenous Dexamethasone for Postoperative Nausea and Vomiting in Total Joint Replacement</article-title>,&#8221; <source>Arthroplast Today</source><volume>5</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>211</fpage>&#8211;<lpage>215</lpage>.<pub-id pub-id-type="pmid">31286046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.artd.2019.01.007</pub-id><pub-id pub-id-type="pmcid">PMC6588720</pub-id></mixed-citation></ref><ref id="os70113-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="os70113-cit-0027"><string-name name-style="western"><given-names>N. D.</given-names><surname>Heckmann</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Piple</surname></string-name>, et&#160;al., &#8220;<article-title>Is Intraoperative Dexamethasone Utilization Associated With Increased Rates of Periprosthetic Joint Infection Following Total Joint Arthroplasty?</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>38</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>224</fpage>.<pub-id pub-id-type="pmid">36031084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2022.08.028</pub-id></mixed-citation></ref><ref id="os70113-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="os70113-cit-0028"><string-name name-style="western"><given-names>M. R.</given-names><surname>Klement</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Wilkens</surname></string-name>, <string-name name-style="western"><given-names>Y. A.</given-names><surname>Fillingham</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Manrique</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Austin</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Parvizi</surname></string-name>, &#8220;<article-title>Intraoperative Dexamethasone Reduces Readmission Rates Without Affecting Risk of Thromboembolic Events or Infection After Total Joint Arthroplasty</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>33</volume>, no. <issue>10</issue> (<year>2018</year>): <fpage>3252</fpage>&#8211;<lpage>3256</lpage>.<pub-id pub-id-type="pmid">29885970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arth.2018.05.016</pub-id></mixed-citation></ref><ref id="os70113-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="os70113-cit-0029"><string-name name-style="western"><given-names>S.</given-names><surname>Arumugam</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Woolley</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Vellanky</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Cremins</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Dulipsingh</surname></string-name>, &#8220;<article-title>Comparison of Dexamethasone 4mg vs 8mg Doses in Total Joint Arthroplasty Patients: A Retrospective Analysis</article-title>,&#8221; <source>Cureus</source><volume>12</volume>, no. <issue>9</issue> (<year>2020</year>): <elocation-id>e10295</elocation-id>.<pub-id pub-id-type="pmid">33047085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.10295</pub-id><pub-id pub-id-type="pmcid">PMC7540179</pub-id></mixed-citation></ref><ref id="os70113-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="os70113-cit-0030"><string-name name-style="western"><given-names>V.</given-names><surname>Williams</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Uddin Ansari</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jaju</surname></string-name>, et&#160;al., &#8220;<article-title>Impact of Perioperative Dexamethasone on Hospital Length of Stay and Glycemic Control in Patients With Type 2 Diabetes Undergoing Total Hip Arthroplasty</article-title>,&#8221; <source>J Patient Cent Res Rev</source><volume>10</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>4</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">36714000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17294/2330-0698.1971</pub-id><pub-id pub-id-type="pmcid">PMC9851389</pub-id></mixed-citation></ref><ref id="os70113-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="os70113-cit-0031"><string-name name-style="western"><given-names>A.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Dai</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Tseng</surname></string-name>, et&#160;al., &#8220;<article-title>Systemic Effects of Perineural Glucocorticoids on Fasting Serum Glucose, Potassium, and White Blood Cell Count in Total Hip Arthroplasty</article-title>,&#8221; <source>Journal of Pain Research</source><volume>16</volume> (<year>2023</year>): <fpage>553</fpage>&#8211;<lpage>561</lpage>.<pub-id pub-id-type="pmid">36846205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S395336</pub-id><pub-id pub-id-type="pmcid">PMC9946012</pub-id></mixed-citation></ref><ref id="os70113-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="os70113-cit-0032"><string-name name-style="western"><given-names>T. J.</given-names><surname>Wasfie</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Groton</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Cwalina</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Hella</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Barber</surname></string-name>, &#8220;<article-title>Efficacy of Preoperative Usage of Dexamethasone in Diabetic Patients Undergoing Total Hip or Knee Arthroplasty for Control of Nausea and Vomiting</article-title>,&#8221; <source>American Surgeon</source><volume>87</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>336</fpage>&#8211;<lpage>340</lpage>.<pub-id pub-id-type="pmid">32967432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0003134820947391</pub-id></mixed-citation></ref><ref id="os70113-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="os70113-cit-0033"><string-name name-style="western"><given-names>Y.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Pei</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Huang</surname></string-name>, &#8220;<article-title>Is a Split&#8208;Dose Intravenous Dexamethasone Regimen Superior to a Single High Dose in Reducing Pain and Improving Function After Total Hip Arthroplasty? A Randomized Blinded Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Bone &amp; Joint Journal</source><volume>102</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>1497</fpage>&#8211;<lpage>1504</lpage>.<pub-id pub-id-type="pmid">33135436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1302/0301-620X.102B11.BJJ-2020-1078.R1</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>